RxDoctor Payments Data

Saba Lodhi, MD

Pulmonary Disease · Wenatchee, WANPI 1609071042

Payments from drug & device makers

$3,894in general payments, 2019–2025

Across 13 payments — averaging $299.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$2K
  • Intuitive Surgical$1K
  • Inari Medical, Inc.$235
  • Boehringer Ingelheim$36
  • ERBE USA Inc$31
  • Pulmonx Corporation$12

What the payments were for

  • Travel & lodging$1,33876%
  • Food & beverage$37722%
  • Education$362%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Incyte Corporation1$2,143
Intuitive Surgical8$1,438
Inari Medical, Inc.1$235
Boehringer Ingelheim1$36
ERBE USA Inc1$31
Pulmonx Corporation1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,894 in reported general payments places this provider in the 75th percentile of 275 pulmonary disease providers in Washington.

See all pulmonary disease providers in Washington

Medicare billing

Part B allowed, 2024
$86,893
Medicare patients
315
Services billed
1,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag12$274,831
Prolastin CAlpha-1-Proteinase Inhibitor13$86,938
Trelegy ElliptaFluticasone/Umeclidin/Vilanter84$60,463
NucalaMepolizumab16$57,604
Spiriva RespimatTiotropium Bromide91$55,483
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr80$37,048
Ambrisentan23$29,780
Stiolto RespimatTiotropium Br/Olodaterol Hcl55$26,684
DuleraMometasone/Formoterol44$14,747
Combivent RespimatIpratropium/Albuterol Sulfate11$10,885
Fluticasone-SalmeterolFluticasone Propion/Salmeterol80$10,518
Incruse ElliptaUmeclidinium Bromide25$9,089
Breo ElliptaFluticasone/Vilanterol22$8,521
SymbicortBudesonide/Formoterol Fumarate22$8,252
Advair HfaFluticasone Propion/Salmeterol18$5,878

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$36$93,052157 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 275 pulmonary disease providers in Washington.

Other pulmonary disease in Wenatchee

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →